Vectibix (panitumumab) / Amgen, Takeda, Dr. Reddy’s - LARVOL DELTA

First-line panitumumab versus cetuximab for all RAS wild-type metastatic colorectal cancer: Survival and metastatic-site resection in a Taiwanese Multicenter cohort (ESMO Asia 2025) - "First-line panitumumab and cetuximab achieved similar OS, but panitumumab was consistently associated with higher metastatic-site resection rates. Metastasectomy was linked to markedly prolonged survival, supporting panitumumab's potential in conversion therapy."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • EGFR • RAS

Evaluation of Pafolacianine (Cytalux®) for Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma: A Negative Study with Important Clinical Implications. (PubMed, Mol Imaging Biol) - "Negative studies such as this are essential for evidence-based clinical decision-making, preventing unnecessary resource allocation and potential patient exposure to ineffective interventions. These findings inform the broader fluorescence-guided surgery field and support continued investigation of alternative targeting strategies for HNSCC."

Journal • Head and Neck Cancer • Oncology • Otorhinolaryngology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • FOLR1

Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT06978400 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF

FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC). (ASCO-GI 2026) - P2/3 | "Funded by Cancer Research UK funded the FOxTROT trial, Amgen supported both the study and provided panitumumab and funded extended biomarker testing, Yorkshire Cancer Research supported the pathology work Clinical Trial Registration Number: NCT00647530 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • ERBB3 • HER-2 • RAS

Estimating longitudinal biomarker effects using a Lasso-network constrained time-Varying mixed effects model. (PubMed, J Appl Stat) - "Our method is further applied to real data from a randomized clinical trial of patients with metastatic colorectal cancer (mCRC), treated with standard chemotherapy with or without panitumumab. This case study demonstrates how our approach adeptly captures the time-varying impacts of critical circulating biomarkers on treatment outcomes, specifically tumor size reduction."

Biomarker • Clinical • Journal • Colorectal Cancer • Oncology • Solid Tumor

Pneumomediastinum Masquerading As Superior Vena Cava Obstruction in a Patient With Metastatic Colorectal Cancer: A Diagnostic Challenge. (PubMed, Cureus) - "We present the case of a 57-year-old woman with metastatic recurrent colorectal carcinoma receiving palliative FOLFIRI (folinic acid, fluorouracil, and irinotecan) and panitumumab who was admitted with recurrent respiratory infections. Due to persistent hilar disease and recurrent respiratory compromise, the thoracic multidisciplinary team later proposed palliative surgical debulking. This case highlights the importance of prompt imaging and multidisciplinary assessment in differentiating pneumomediastinum from SVCO to avoid unnecessary invasive interventions."

Journal • Asthma • Colorectal Cancer • Cough • Gastrointestinal Disorder • Immunology • Infectious Disease • Mood Disorders • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thoracic Cancer

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026 (OncLive) - "'[During 2025], adjuvant therapy regimens from the [phase 3] ATOMIC trial [NCT02912559]—FOLFOX or CAPEOX in combination with atezolizumab—were added in stage III dMMR/MSI-H colon cancer. This change represents the addition of checkpoint inhibitor therapies at earlier points of the patient journey.' Al B. Benson, III, MD...said in a statement to OncLive."

Audio

Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study. (PubMed, Curr Oncol) - "dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs."

IO biomarker • Journal • MSI-H • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • BRAF • MSI

concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Zhejiang University

Checkpoint inhibition • IO biomarker • New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer. (PubMed, J Clin Oncol) - No abstract available

FDA event • Harmonization • Journal • Colorectal Cancer • Oncology • Solid Tumor

Breakthroughs in KRAS G12C-mutant advanced colorectal cancer: from mechanisms to clinical practice (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi) - "Recent phase I/II trials of KRAS G12C inhibitors have shown promising results, and the phase III CodeBreaK 300 study confirmed that sotorasib combined with panitumumab significantly improved efficacy compared with standard treatment, establishing a new therapeutic option for KRAS G12C-mutant metastatic CRC. Strategies under investigation include targeting alternative signaling pathways, developing next-generation inhibitors and specific degraders, and exploring multi-mechanism or multi-target combination strategies. This review systematically outlines the development of KRAS G12C inhibitors in mCRC, summarizes resistance mechanisms, and discusses emerging combination regimens, aiming to provide a theoretical basis and future directions for treatment optimization."

Journal • Review • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med) - "Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data."

Biomarker • Journal • Colorectal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • ANXA2 • CDC37 • CTNNB1 • CTNND1 • ENO1 • HSP90AA1 • HSP90AB1 • HSPA4 • HSPA8 • ITGB1 • ITGB2 • LRIG1 • NCAPD2 • NT5C • POLD1 • PPM1G • PRKDC • PTPN1 • YBX1 • YWHAZ

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov) - P2 | N=34 | Active, not recruiting | Sponsor: University of Wisconsin, Madison | Recruiting ➔ Active, not recruiting | N=71 ➔ 34 | Trial completion date: Oct 2033 ➔ Oct 2029 | Trial primary completion date: Oct 2033 ➔ Oct 2029

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS • MSI • NRAS

Short- and Long-Term Outcomes of Neoadjuvant Chemotherapy in Operable Locally Advanced Colon Cancer: A Systematic Review. (PubMed, Cureus) - "The addition of targeted therapy based on biomarker status (e.g., panitumumab in KRAS-wildtype tumors) demonstrated significant improvements in DFS and OS...Its efficacy is highly dependent on careful patient selection based on disease stage and molecular characteristics. Future research should focus on randomized trials in high-risk populations and the integration of personalized treatment approaches."

Journal • Review • Colon Cancer • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor • KRAS

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=2 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Trial primary completion date: Dec 2025 ➔ Jul 2025

Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS • RAS

A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database (ISPOR-EU 2025) - "Regarding treatments, all treatment lines combined, 66.2% of patients received bevacizumab, 19.0% panitumumab, 15.6% cetuximab, and fewer patients received other treatments including, aflibercept (8.1%) and pembrolizumab (4.1%). This study provides a recent update of prevalence and region distribution of mCRC treated patients in France highlighting the predominant use of bevacizumab to treat mCRC in France irrespective of tumor sidedness and treatment line."

Metastases • Retrospective data • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

A Case of Peristomal Abscess after Treatment with Panitumumab (PubMed, Gan To Kagaku Ryoho) - "Because the area where the faceplate is applied can only be observed in detail during stoma care, it is important to identify skin lesions early. Additionally, it is important to collaborate closely with the WOCN, primary care physicians, and dermatologists."

Journal • Colorectal Cancer • Oncology • Pain • Rectal Cancer • Solid Tumor

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). (PubMed, Eur J Cancer) - "The present analysis of BRAFV600E-mut mCRC suggests a survival benefit from anti-EGFR- or anti-VEGF-directed antibodies in patients with LSPT. This effect was not observed in RSPT, where patients showed a clearly greater benefit from bevacizumab."

Journal • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor

Factors Associated with Hypophosphatemia Among Patients with Malignancy on Antineoplastic Agents (KIDNEY WEEK 2025) - "Conclusion Panitumumab, fludarabine, durvalumab, nivolumab, cyclophosphamide, and etoposide were associated with hypophosphatemia. Although the results might be affected by practice patterns of our facility, phosphate levels should be monitored when these agents are prescribed, especially to elderly patients with hypoalbuminemia. Anti-neoplastic agents associated with hypophosphatemia"

Clinical • Oncology • Renal Disease

Cancer Treatment-Associated Hypomagnesemia: Analysis from a Large Pharmacovigilance Database (KIDNEY WEEK 2025) - "The drugs with the highest IC025 were panitumumab (6.22), cetuximab (4.85), and cisplatin (3.26) ( Figure ). Gastrointestinal and hepatobiliary cancers (40.1%) were the most common types of cancer, followed by lung (14.1%), and head and neck cancer (13.4%).Time to onset of hypomagnesemia was the shortest in those in the lowest age group (≤17 years). Conclusion Hypomagnesemia was most frequent with conventional chemotherapy and anti-EGFR mABs; thus, patients treated with these agents should be monitored for hypomagnesemia, and may benefit from preventative or therapeutic strategies."

Adverse events • Biliary Cancer • Head and Neck Cancer • Oncology • Solid Tumor

Utility of Acetazolamide in Lithium-Induced Arginine Vasopressin Resistance (KIDNEY WEEK 2025) - "Thiazides were avoided due to severe hypomagnesemia (0.9 mg/dL), attributed to diarrhea and panitumumab, and concern for Li toxicity. Desmopressin and amiloride failed to improve polyuria, and the patient required intravenous (IV) dextrose water to maintain normonatremia for a week due to poor oral intake...Although current evidence is largely from animal and congenital models, this case demonstrates successful use in an adult, allowing rapid IV fluid weaning and potentially shortening hospitalization. Acetazolamide may also offer a reduced risk of Li toxicity as it inhibits renal tubular reabsorption of Li, and fewer electrolyte disturbances compared to thiazide-based therapy, suggesting its potential for broader use in difficult-to-manage Li-induced AVR."

Anal Carcinoma • Bipolar Disorder • CNS Disorders • Infectious Disease • Mood Disorders • Nephrology • Psychiatry • Pulmonary Disease • Renal Disease • Squamous Cell Carcinoma

BDTX-4933-101: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (clinicaltrials.gov) - P1/2 | N=554 | Recruiting | Sponsor: Institut de Recherches Internationales Servier | Phase classification: P1 ➔ P1/2 | N=100 ➔ 554 | Trial completion date: Dec 2026 ➔ Jun 2028 | Trial primary completion date: Jun 2026 ➔ Jun 2028

Enrollment change • Monotherapy • Phase classification • Trial completion date • Trial primary completion date • Brain Cancer • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thyroid Gland Carcinoma • BRAF • KRAS • NRAS

Oncology (Amgen Press Release) - "Vectibix (panitumumab) sales increased 1% year-over-year to $284 million in the third quarter; KYPROLIS (carfilzomib) sales decreased 5% year-over-year to $359 million in the third quarter, driven by lower volume; LUMAKRAS /LUMYKRAS (sotorasib) sales decreased 2% year-over-year to $96 million in the third quarter; XGEVA (denosumab) sales were flat year-over-year at $539 million in the third quarter...Nplate (romiplostim) sales were flat year-over-year at $457 million in the third quarter. U.S. government orders were $90 million in Q3'25 compared to $128 million in Q3'24...IMDELLTRA (tarlatamab-dlle)/IMDYLLTRA (tarlatamab) generated $178 million of sales in the third quarter. Sales increased 33% quarter-over-quarter, primarily driven by volume growth; MVASI (bevacizumab-awwb) sales increased 9% year-over-year to $213 million in the third quarter, driven by favorable changes to estimated sales deductions."

Sales • Cervical Cancer • Colorectal Cancer • Glioblastoma • Lung Non-Squamous Non-Small Cell Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma. (PubMed, Int J Clin Oncol) - No abstract available

Japanese regulatory • Journal • Bladder Cancer • Brain Cancer • Colorectal Cancer • Genito-urinary Cancer • Glioma • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor

Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO (ESMO 2025) - P2 | "Conclusions Anti-EGFR re-tx is an option in the continuum-of-care of chemorefractory mCRC pts with RAS and BRAF wt tumors, with no alterations of acquired resistance in their ctDNA. A clearly better tx sequence was not identified, except for the subgroup of pts with an anti-EGFR-free interval ≤ 6 mos where the rego-first sequence seems preferable."

Circulating tumor DNA • Clinical • Late-breaking abstract • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • BRAF • RAS